Orum Therapeutics

About Orum Therapeutics

Orum Therapeutics is a clinical-stage biotech company focused on pioneering a novel class of Antibody-Drug Conjugates (ADCs) to treat serious diseases, aiming to ascend to new heights in therapeutic innovation.

Products & Services

TPD² (Cell Selective Degradation):A breakthrough protein degrader approach designed to improve efficacy, safety, and half-life compared to conventional targeted protein degraders.

Pipeline of Degrader Antibody Conjugates:A portfolio of highly differentiated products combining protein degraders with the precision of antibodies to change the face of disease treatment.

ORM-1153:A CD123-targeting Degrader Antibody Conjugate showing potent and selective antitumor activity for Acute Myeloid Leukemia, as presented in preclinical data.

Specialties

Antibody-Drug Conjugates (ADCs) Protein Degraders Cell Selective Degradation Therapeutic Innovation for Serious Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Convertible Preferred Stock T: - FT: Convertible Preferred Stock	A: 100 MR: - FA: approximately US$100 million FAN: 100	D: 2025-12-18 FD: 2025-12-18	10 investors

Convertible Preferred Stock Latest

2025-12-18

$100

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Susan Best

Human Resources

LinkedIn (Pro only)

O

Olaf Christensen

CMO

LinkedIn (Pro only)

G

Greg Dwyer

Head of Business Development

LinkedIn (Pro only)

M

Martin Intae Jeong

CFO

S

SJ Lee

CEO

C

Chris Martin

Head of Legal

View 51 more team members with Pro

Unlock Full Team Directory

Recent News